Onco-Innovations Stock Price, News & Analysis

Onco-Innovations Limited announced that co-founders of its subsidiary Inka Health Corp. published a study examining the applicability of lung cancer clinical trial outcomes to real-world populations. The study, titled 'Global Transportability of Clinical Trial Outcomes to Real-World Lung Cancer Populations,' demonstrated strong predictive performance with less than 1% variation in matching real-world outcomes over 30 months. The research supports the development of SynoGraph, Inka Health's causal AI platform, which aims to enhance drug development through real-world analytics. The study's methodology focuses on optimizing trial design and defining relevant populations to reduce development pipeline risks.

Onco-Innovations (ONNVF) has partnered with the University of Alberta and Cross Cancer Institute to conduct preclinical studies expanding their PNKP inhibitor technology research into hard-to-treat cancers, initially focusing on glioblastoma multiforme (GBM). The research, set to begin in Q3 2025, will be led by Dr. Michael Weinfeld, a Senior Scientist at Alberta Health Services and the original discoverer of the PNKP inhibitor technology. The study aims to evaluate the therapeutic potential of their second-generation nanoparticle formulation in GBM, which affects over 200,000 people worldwide annually and has a very low five-year survival rate. The research will assess the compound's pharmacological characteristics, DNA damage enhancement in tumor models, effects on normal brain tissue, and potential combination strategies with existing therapies.

Onco-Innovations' subsidiary Inka Health is launching a global AI-oncology consortium called Predicting Oncology Outcomes using Multimodal AI (PROmAI). The initiative aims to unite pharmaceutical companies, academic institutions, and data science experts to advance predictive modeling in cancer research. PROmAI will focus on developing AI approaches that integrate real-world and clinical trial data from multiple sources to enhance predictive accuracy and regulatory relevance in translational oncology. The consortium seeks to establish standards for AI transparency and trustworthiness in medical research while accelerating progress toward personalized cancer care. The initiative is currently in its formative phase, with discussions ongoing with potential founding members.

Onco-Innovations (ONNVF) has initiated manufacturing of preclinical testing material for its PNKP inhibitor technology through Dalton Pharma Services. The project aims to produce 50 grams of their proprietary inhibitor A83B4C63 for preclinical studies and IND submission preparation.

Previous research from 2021 demonstrated promising results: the nanoparticle-formulated PNKP inhibitor significantly extended median survival in PTEN-deficient colorectal cancer-bearing mice to 60 days vs. 23 days in untreated controls. Additionally, when combined with radiation therapy, it enhanced tumor growth delay without significant toxicity to healthy tissues.

Onco-Innovations (ONNVF) has extended its marketing engagement with MCS Market Communication Service GmbH for online marketing services. The extended services include campaign creation, marketing materials production, and research and analytics. The program will run until June 30, 2025, or until budget exhaustion. Onco-Innovations has paid EUR 500,000 for this extension. The services will be delivered through digital channels, including Google Ads and native advertising. No securities were issued as compensation for these services.

Onco-Innovations (ONNVF) has appointed Professor Steven Jones as Senior Scientific Advisor to strengthen its AI-powered precision oncology initiatives. Jones, currently serving as Co-Director of the Genome Sciences Centre and Head of Bioinformatics at BC Cancer Research Institute, is a distinguished researcher in genomics and cancer research. As Senior Scientific Advisor, he will provide scientific leadership for Onco's oncology genomics and AI initiatives, particularly focusing on the company's flagship AI platform SynoGraph through its subsidiary Inka Health. His responsibilities include guiding scientific direction, fostering research partnerships, supporting fundraising efforts, and representing the company in scientific communities. Jones brings significant expertise as a Fellow of the Royal Society of Canada and is consistently recognized as one of the world's most highly cited researchers by Clarivate Analytics.

Onco-Innovations Limited (CSE:ONCO) has announced the transfer of its common shares listing from the Canadian Securities Exchange (CSE) to Cboe Canada Inc. The transition will take effect on May 22, 2025, with the company maintaining its existing ticker symbol \"ONCO\". The voluntary delisting from CSE is scheduled for May 21, 2025.

Cboe Canada, a Tier 1 stock exchange within the global Cboe Markets network, provides advanced market infrastructure and real-time data solutions, including its ETF Market Canada platform that analyzes over 1,200 Canadian ETFs. CEO Thomas O'Shaughnessy emphasized that this strategic move aims to enhance the company's visibility in capital markets, broaden its investor base, and strengthen institutional engagement.

Onco-Innovations (OTCQB:ONNVF) has announced that its subsidiary Inka Health has secured a new analytical work contract with AstraZeneca Canada on March 20, 2025. The contract focuses on advancing real-world evidence (RWE) research in regulatory science.

Under the new agreement, Inka Health will develop a peer-reviewed scientific manuscript examining how international RWE is utilized in submissions to Canada's Drug Agency (CDA). This project expands on previous collaborative work that addressed bias and generalizability challenges in non-local RWE, which has been accepted for presentation at ISPOR 2025 (May 11-15, 2025).

The renewed engagement demonstrates AstraZeneca's confidence in Inka Health's capabilities to support drug evaluation, submission strategies, and evidence planning within Canada's regulatory framework.

Onco-Innovations (OTCQB:ONNVF) has announced the appointment of Dr. James Orbinski to its Scientific and Clinical Advisory Board. Dr. Orbinski, a former International President of Médecins Sans Frontières (MSF), is notable for accepting the Nobel Peace Prize on behalf of MSF in 1999.

Currently a Full Professor at Temerty School of Medicine and the University of Toronto, Dr. Orbinski brings extensive experience in global health and humanitarian medicine. He was the founding Director of the Dahdaleh Institute for Global Health Research and co-chaired MSF's Neglected Diseases Working Group. His work with the Drugs for Neglected Diseases Initiative (DNDi) has led to the development of 13 treatments for 6 deadly diseases since 2003.

An Officer of the Order of Canada and recipient of the Meritorious Service Cross, Dr. Orbinski will provide strategic insight for Onco's scientific programs and global oncology innovations.